Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes(Tang-Du Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes(Tang-Du Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell(Chinese PLA General Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell(Chinese PLA General Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence revi
9 min read
Cytokine-Induced Memory-Like Natural Killer Cells(Cincinnati Children's Hospital Medical Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Cytokine-Induced Memory-Like Natural Killer Cells(Cincinnati Children's Hospital Medical Center): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
67Cu-PSMA Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
67Cu-PSMA: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Umbilical Cord-derived Mesenchymal Stem Cell(The Children's Hospital of Zhejiang University School of Medicine) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Umbilical Cord-derived Mesenchymal Stem Cell(The Children's Hospital of Zhejiang University School of Medicine): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidenc
9 min read
Autologous TCM-enriched CD8+ T cells xpressing CD19-specific CAR(City of Hope National Medical Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Autologous TCM-enriched CD8+ T cells xpressing CD19-specific CAR(City of Hope National Medical Center): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review
9 min read
QL-H118 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
QL-H118: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
MRG-007 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
MRG-007: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
KF-0210 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
KF-0210: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
TTRNA-DC vaccine(University of Florida) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
TTRNA-DC vaccine(University of Florida): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position
9 min read
SEQ-400 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
SEQ-400: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
MT-0814 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
MT-0814: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.